| abstract |
A castration resistant relapsed prostate cancer therapeutic agent, a male contraceptive agent, and a myasthenia gravis therapeutic agent containing an IκB kinase α activation inhibitor (IKKα activation inhibitor) as an active ingredient. An adenosine analog represented by the following formula having a selective inhibitory action on IκB kinase α, norlisteromycin (NAM) is treated with castration-resistant relapsed prostate cancer, a male contraceptive, and Used as a treatment for myasthenia gravis. [Selection] Figure 2 |